Hydroxyurea enhances the activity of acyclovir and cidofovir against herpes simplex virus type 1 resistant strains harboring mutations in the thymidine kinase and/or the DNA polymerase genes

Antiviral Research

Volumn 77, Issue 1, 2008, Pages 77-80

  Sergerie, Yan ^a   Boivin, Guy ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

Acyclovir; Cidofovir; Herpes simplex virus; Hydroxyurea; Resistance

Indexed keywords

ACICLOVIR; CIDOFOVIR; DNA POLYMERASE; FOSCARNET; HYDROXYUREA; OXIDOREDUCTASE INHIBITOR; THYMIDINE KINASE;

ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; GENE MUTATION; HERPES SIMPLEX VIRUS 1; IC 50; NONHUMAN; PRIORITY JOURNAL; VIRUS GENE; VIRUS MUTANT; VIRUS MUTATION; VIRUS RESISTANCE; VIRUS STRAIN;

ACYCLOVIR; ANTIVIRAL AGENTS; CYTOSINE; DNA-DIRECTED DNA POLYMERASE; DRUG COMBINATIONS; DRUG RESISTANCE, VIRAL; FOSCARNET; HERPESVIRUS 1, HUMAN; HUMANS; HYDROXYUREA; MUTATION; PHOSPHONIC ACIDS; RIBONUCLEOTIDE REDUCTASES; THYMIDINE KINASE;

HUMAN HERPESVIRUS 1; SIMPLEXVIRUS;

EID: 37449000072     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.antiviral.2007.08.009     Document Type: Article

References (27)

1. Belt R.J., Haas C.D., Kennedy J., and Taylor S. Studies of hydroxyurea administered by continuous infusion: toxicity, pharmacokinetics, and cell synchronization. Cancer 46 (1980) 455-462
2. Bestman-Smith J., and Boivin G. Drug resistance patterns of recombinant herpes simplex virus DNA polymerase mutants generated with a set of overlapping cosmids and plasmids. J. Virol. 77 (2003) 7820-7829
3. Brandt C.R., Kintner R.L., Pumfery A.M., Visalli R.J., and Grau D.R. The herpes simplex virus ribonucleotide reductase is required for ocular virulence. J. Gen. Virol. 72 (1991) 2043-2049
4. Chrisp P., and Clissold S.P. Foscarnet. A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis. Drugs 41 (1991) 104-129
5. De Clercq E. Trends in the development of new antiviral agents for the chemotherapy of infections caused by herpesviruses and retroviruses. Rev. Med. Virol. 5 (1995) 149-164
6. De Clercq E., Holy A., Rosenberg I., Sakuma T., Balzarini J., and Maudgal P.C. A novel selective broad-spectrum anti-DNA virus agent. Nature 323 (1986) 464-467
7. De Clercq E., Sakuma T., Baba M., Pauwels R., Balzarini J., Rosenberg I., and Holy A. Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines. Antiviral Res. 8 (1987) 261-272
8. Gao W.Y., Cara A., Gallo R.C., and Lori F. Low levels of deoxynucleotides in peripheral blood lymphocytes: a strategy to inhibit human immunodeficiency virus type 1 replication. Proc. Natl. Acad. Sci. USA 90 (1993) 8925-8928
9. Gao W.Y., Johns D.G., and Mitsuya H. Anti-human immunodeficiency virus type 1 activity of hydroxyurea in combination with 2′,3′-dideoxynucleosides. Mol. Pharmacol. 46 (1994) 767-772
10. Idowu A.D., Fraser-Smith E.B., Poffenberger K.L., and Herman R.C. Deletion of the herpes simplex virus type 1 ribonucleotide reductase gene alters virulence and latency in vivo. Antiviral Res. 17 (1992) 145-156
11. Jacobson J.G., Leib D.A., Goldstein D.J., Bogard C.L., Schaffer P.A., Weller S.K., and Coen D.M. A herpes simplex virus ribonucleotide reductase deletion mutant is defective for productive acute and reactivatable latent infections of mice and for replication in mouse cells. Virology 173 (1989) 276-283
12. Johns D., and Gao W. Selective depletion of DNA precursors: an evolving strategy for potentiation of dideoxynucleoside activity against human immunodeficiency virus. Biochem. Pharmacol. 55 (1998) 1551-1556
13. Lagergren J., and Reichard P. Purine deoxyribonucleosides counteract effects of hydroxyurea on deoxyribonucleoside triphosphate pools and DNA synthesis. Biochem. Pharmacol. 36 (1987) 2985-2991
14. Lori F., and Lisziewicz J. Cellular factors: targets for the treatment of HIV infection. Antivir. Ther. 3 Suppl. 4 (1998) 81-92
15. Lori F., Malykh A., Cara A., Sun D., Weinstein J.N., Lisziewicz J., and Gallo R.C. Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication. Science 266 (1994) 801-805
16. Lori F., Kelly L.M., Foli A., and Lisziewicz J. Safety of hydroxyurea in the treatment of HIV infection. Expert Opin. Drug Saf. 3 (2004) 279-288
17. Malley S.D., Grange J.M., Hamedi-Sangsari F., and Vila J.R. Suppression of HIV production in resting lymphocytes by combining didanosine and hydroxamate compounds. Lancet 343 (1994) 1292
18. Neyts J., and De Clercq E. Hydroxyurea potentiates the antiherpesvirus activities of purine and pyrimidine nucleoside and nucleoside phosphonate analogs. Antimicrob. Agents Chemother. 43 (1999) 2885-2892
19. Palmer S., Shafer R.W., and Merigan T.C. Hydroxyurea enhances the activities of didanosine, 9-[2-(phosphonylmethoxy)ethyl]adenine, and 9-[2-(phosphonylmethoxy)propyl]adenine against drug-susceptible and drug-resistant human immunodeficiency virus isolates. Antimicrob. Agents Chemother. 43 (1999) 2046-2050
20. Pancheva S., and Venkova T. Enhancement of antiherpetic activity of cytarabine by hydroxyurea in human embryonic skin-muscle fibroblasts. Zentralbl. Bakteriol. 289 (2000) 845-848
21. Safrin S., Kemmerly S., Plotkin B., Smith T., Weissbach N., De Veranez D., Phan L.D., and Cohn D. Foscarnet-resistant herpes simplex virus infection in patients with AIDS. J. Infect. Dis. 169 (1994) 193-196
22. Schmit I., and Boivin G. Characterization of the DNA polymerase and thymidine kinase genes of herpes simplex virus isolates from AIDS patients in whom acyclovir and foscarnet therapy sequentially failed. J. Infect. Dis. 180 (1999) 487-490
23. Sergerie Y., and Boivin G. Thymidine kinase mutations conferring acyclovir resistance in herpes simplex type 1 recombinant viruses. Antimicrob. Agents Chemother. 50 (2006) 3889-3892
24. Villani P., Maserati R., Regazzi M.B., Giacchino R., and Lori F. Pharmacokinetics of hydroxyurea in patients infected with human immunodeficiency virus type I. J. Clin. Pharmacol. 36 (1996) 117-121
25. Xiong X., Smith J.L., Kim C., Huang E.S., and Chen M.S. Kinetic analysis of the interaction of cidofovir diphosphate with human cytomegalovirus DNA polymerase. Biochem. Pharmacol. 51 (1996) 1563-1567
26. Xiong X., Smith J.L., and Chen M.S. Effect of incorporation of cidofovir into DNA by human cytomegalovirus DNA polymerase on DNA elongation. Antimicrob. Agents Chemother. 41 (1997) 594-599
27. Yamada Y., Kimura H., Morishima T., Daikoku T., Maeno K., and Nishiyama Y. The pathogenicity of ribonucleotide reductase-null mutants of herpes simplex virus type 1 in mice. J. Infect. Dis. 164 (1991) 1091-1097